CORC

浏览/检索结果: 共62条,第1-10条 帮助

限定条件    
已选(0)清除 条数/页:   排序方式:
Phase III Randomized AUGMENT Study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma 会议论文
作者:  Gribben, J.;  Trneny, M.;  Izutsu, K.;  Fowler, N. H.;  Hong, X.
收藏  |  浏览/下载:22/0  |  提交时间:2019/12/05
Circulating tumor DNA to predict response and resistance by anti-PD-1 therapy in Chinese relapsed/refractory classic Hodgkin lymphoma. 会议论文
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), MAY 31-JUN 04, 2019
作者:  Su, Hang;  Song, Yongping;  Jiang, Wenqi;  Sun, Xiuhua;  Qian, Wenbin
收藏  |  浏览/下载:12/0  |  提交时间:2019/12/31
Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study. 会议论文
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), MAY 31-JUN 04, 2019
作者:  Su, Hang;  Song, Yongping;  Jiang, Wenqi;  Sun, Xiuhua;  Qian, Wenbin
收藏  |  浏览/下载:12/0  |  提交时间:2019/12/31
OLAPARIB MAINTENANCE MONOTHERAPY IMPROVES PROGRESSION-FREE SURVIVAL (PFS) IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSROC): SOLO2 STUDY - CHINA COHORT 会议论文
作者:  Liu, J.;  Yin, R.;  Wu, L.;  Zhu, J.;  Lou, G.
收藏  |  浏览/下载:3/0  |  提交时间:2019/12/05
Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study 会议论文
作者:  Song, Yuqin;  Gao, Quanli;  Zhang, Huilai;  Fan, Lei;  Zhou, Jianfeng
收藏  |  浏览/下载:5/0  |  提交时间:2019/12/05
Safety and efficacy of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma from China 会议论文
作者:  Song, Y.;  Hong, X.;  Huang, H.;  Bai, B.;  Zhang, H.
收藏  |  浏览/下载:3/0  |  提交时间:2019/12/05
AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R-2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma 会议论文
作者:  Leonard, John P.;  Trneny, Marek;  Izutsu, Koji;  Fowler, Nathan H.;  Hong, Xiaonan
收藏  |  浏览/下载:10/0  |  提交时间:2019/12/05
Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma 会议论文
作者:  Zhao, Wan-Hong;  Liu, Jie;  Wang, Bai-Yan;  Chen, Yin-Xia;  Cao, Xing-Mei
收藏  |  浏览/下载:12/0  |  提交时间:2019/11/26
Mutational Landscape and Temporal Evolution during Treatment of Relapsed Acute Lymphoblastic Leukemia 会议论文
BLOOD, 2018-11-29
作者:  Li, Benshang;  Li, Yongjin;  Shen, Shuhong;  Zhang, Yingchi;  Brady, Samuel
收藏  |  浏览/下载:15/0  |  提交时间:2020/01/03
Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from t 会议论文
BLOOD, 2018-11-29
作者:  Fu, Weijun;  Lu, Jin;  Jin, Jie;  Xu, Yan;  Wu, Depei
收藏  |  浏览/下载:6/0  |  提交时间:2020/01/03


©版权所有 ©2017 CSpace - Powered by CSpace